CT-Based Radiomic Signature as a Prognostic Factor in Stage IV ALK-Positive Non-small-cell Lung Cancer Treated With TKI Crizotinib: A Proof-of-Concept Study

CT-Based Radiomic Signature as a Prognostic Factor in Stage IV ALK-Positive Non-small-cell Lung Cancer Treated With TKI Crizotinib: A Proof-of-Concept Study

Objectives: To identify a computed tomography (CT)-based radiomic signature for predicting progression-free survival (PFS) in stage IV anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) patients treated with tyrosine kinase inhibitor (TKI) crizotinib.Materials and Methods:...

Full description

Bibliographic Details
Main Authors: Hailin Li, Rui Zhang, Siwen Wang, Mengjie Fang, Yongbei Zhu, Zhenhua Hu, Di Dong, Jingyun Shi, Jie Tian
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-02-01
Series:Frontiers in Oncology
Subjects:
computed tomography
radiomics
non-small-cell lung cancer
tyrosine kinase inhibitor resistance
anaplastic lymphoma kinase
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2020.00057/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2020.00057/full

Similar Items